당뇨황반부종에서의 유리체강내 라니비주맙 주입술의 단기효과

The Short‐Term Efficacy of Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema

Purpose: To evaluate the short-term effect of an intravitreal injection of ranibizumab in the treatment of diabetic macular edema. Methods: Eighteen eyes of 18 patients who underwent intravitreal ranibizumab injection for the treatment of diabetic macular edema between March 1 and November 30, 2009 were retrospectively evaluated. Complete ophthalmic examinations including best corrected visual acuity and optical coherence tomography (OCT) were performed at baseline and follow-up visits at one and three months. Results: The mean visual acuity improved from logMAR 0.74 ± 0.45 at baseline to logMAR 0.44 ± 0.26 at one month and to logMAR 0.42 ± 0.23 at three months (p < 0.05). The mean central macular thickness decreased from 429.5 ± 71.9 μm at baseline to 299.9 ± 81.2 μm at one month and to 284.6 ± 82.6 μm at three months (p < 0.05). No adverse side effects were observed following the injections. Conclusions: The observed macular edema and visual acuity improvements demonstrated that intravitreal ranibizumab injection may be useful for the treatment of patients with diabetic macular edema. J Korean Ophthalmol Soc 2010;51(11):1453-1458